{"id":1531,"date":"2024-03-08T20:26:26","date_gmt":"2024-03-08T19:26:26","guid":{"rendered":"https:\/\/inmuno.es\/?page_id=1531"},"modified":"2024-09-29T01:58:48","modified_gmt":"2024-09-28T23:58:48","slug":"journal-of-clinical-immunology","status":"publish","type":"page","link":"https:\/\/inmuno.es\/index.php\/journal-of-clinical-immunology\/","title":{"rendered":"Journal of Clinical Immunology"},"content":{"rendered":"<ul class=\"wp-block-latest-posts__list is-grid columns-4 has-dates has-author wp-block-latest-posts\"><li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/first-in-human-phase-1-randomized-double-blind-placebo-controlled-study-of-tnx-1500-an-fc-modified-anti-cd154-monoclonal-antibody-evaluating-the-safety-tolerability-pharmacokinetics-and-pharm\/\">First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-29T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">29 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 29. doi: 10.1007\/s10875-026-02028-8. Online ahead of print. ABSTRACT Blocking CD154 (CD40L) has the potential to prolong transplanted solid organ graft survival and treat autoimmune diseases. However, first-generation anti-CD154 IgG1 monoclonal antibodies (mAbs) were associated with an increased risk of thrombosis linked to Fc binding to Fc\u03b3RIIa (CD32A). Here, we describe &#8230; <a title=\"First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/first-in-human-phase-1-randomized-double-blind-placebo-controlled-study-of-tnx-1500-an-fc-modified-anti-cd154-monoclonal-antibody-evaluating-the-safety-tolerability-pharmacokinetics-and-pharm\/\" aria-label=\"Read more about First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/27\/immune-dysregulation-and-persistent-symptoms-insights-into-t-cell-dynamics-in-post-covid-among-athletes-from-the-cosmo-s-study\/\">Immune Dysregulation and Persistent Symptoms: Insights into T Cell Dynamics in Post-COVID among Athletes from the CoSmo-S Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-27T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">27 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 27. doi: 10.1007\/s10875-026-02020-2. Online ahead of print. NO ABSTRACT PMID:42043637 | DOI:10.1007\/s10875-026-02020-2<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/25\/three-doses-and-six-months-later-real-world-sars-cov-2-specific-humoral-and-cell-mediated-immunity-in-children-with-inborn-errors-of-immunity\/\">Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-25T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">25 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 25. doi: 10.1007\/s10875-026-02021-1. Online ahead of print. NO ABSTRACT PMID:42034835 | DOI:10.1007\/s10875-026-02021-1<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/23\/hematopoietic-stem-cell-transplantation-achieves-sustained-remission-in-pediatric-ras-associated-autoimmune-lymphoproliferative-disorder-with-life-threatening-complications-a-single-center-case-serie\/\">Hematopoietic Stem Cell Transplantation Achieves Sustained Remission in Pediatric RAS-Associated Autoimmune Lymphoproliferative Disorder with Life-Threatening Complications: a Single-Center Case Series and Literature Review<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-23T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">23 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 23. doi: 10.1007\/s10875-026-02022-0. Online ahead of print. NO ABSTRACT PMID:42026260 | DOI:10.1007\/s10875-026-02022-0<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/22\/translating-host-derived-signals-from-cerebrospinal-fluid-metagenomic-sequencing-into-a-diagnostic-tool-for-autoimmune-encephalitis-in-children\/\">Translating Host-Derived Signals from Cerebrospinal Fluid Metagenomic Sequencing into a Diagnostic Tool for Autoimmune Encephalitis in Children<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-22T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">22 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 22. doi: 10.1007\/s10875-026-02023-z. Online ahead of print. NO ABSTRACT PMID:42018084 | DOI:10.1007\/s10875-026-02023-z<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/21\/adult-onset-of-msmd-caused-by-il-12r%ce%b21-variants-report-of-a-young-woman-with-ntm-infection-lacking-bacille-calmette-guerin-bcg-induced-diseases\/\">Adult Onset of MSMD Caused by IL-12R\u03b21 Variants: Report of a Young Woman with NTM Infection Lacking Bacille Calmette-Gu\u00e9rin (BCG)-induced Diseases<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-21T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">21 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 21. doi: 10.1007\/s10875-026-02009-x. Online ahead of print. NO ABSTRACT PMID:42012700 | DOI:10.1007\/s10875-026-02009-x<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/21\/antigen-microarray-reveals-broad-and-subclinical-autoimmunity-in-patients-with-inborn-errors-of-immunity\/\">Antigen Microarray Reveals Broad and Subclinical Autoimmunity in Patients with Inborn Errors of Immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-21T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">21 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 21. doi: 10.1007\/s10875-026-02024-y. Online ahead of print. NO ABSTRACT PMID:42012563 | DOI:10.1007\/s10875-026-02024-y<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/20\/trem-1-associated-neutrophil-extracellular-trap-formation-is-linked-to-ivig-resistance-in-kawasaki-disease-a-convergent-transcriptomic-and-prospective-validation-study\/\">TREM-1-Associated Neutrophil Extracellular Trap Formation is Linked to IVIG Resistance in Kawasaki Disease: A Convergent Transcriptomic and Prospective Validation Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-20T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">20 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 21. doi: 10.1007\/s10875-026-02025-x. Online ahead of print. ABSTRACT Kawasaki disease (KD) remains the leading cause of acquired heart disease in children. While intravenous immunoglobulin (IVIG) represents standard therapy, approximately 10-20% of patients exhibit treatment refractoriness associated with significantly elevated coronary artery lesion risk. Current risk stratification relies on clinical parameters-fever &#8230; <a title=\"TREM-1-Associated Neutrophil Extracellular Trap Formation is Linked to IVIG Resistance in Kawasaki Disease: A Convergent Transcriptomic and Prospective Validation Study\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/20\/trem-1-associated-neutrophil-extracellular-trap-formation-is-linked-to-ivig-resistance-in-kawasaki-disease-a-convergent-transcriptomic-and-prospective-validation-study\/\" aria-label=\"Read more about TREM-1-Associated Neutrophil Extracellular Trap Formation is Linked to IVIG Resistance in Kawasaki Disease: A Convergent Transcriptomic and Prospective Validation Study\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/20\/phenotypic-heterogeneity-in-cd40-ligand-deficiency-long-term-follow-up-of-a-patient-with-the-c-156g-a-splice-variant\/\">Phenotypic Heterogeneity in CD40 Ligand Deficiency: Long-term Follow-up of a Patient with the c.156G\u2009&gt;\u2009A Splice Variant<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-20T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">20 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 21. doi: 10.1007\/s10875-026-02019-9. Online ahead of print. NO ABSTRACT PMID:42009946 | DOI:10.1007\/s10875-026-02019-9<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/16\/distinct-proteomic-and-transcriptomic-profiles-in-t-cells-and-monocytes-in-patients-with-common-variable-immunodeficiency-an-exploratory-study\/\">Distinct Proteomic and Transcriptomic Profiles in T-cells and Monocytes in Patients with Common Variable Immunodeficiency: an Exploratory Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-16T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">16 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 17. doi: 10.1007\/s10875-026-02016-y. Online ahead of print. NO ABSTRACT PMID:41991796 | DOI:10.1007\/s10875-026-02016-y<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/15\/immunological-manifestations-in-gale-deficiency-extending-the-spectrum-beyond-thrombocytopenia-and-galactosemia\/\">Immunological Manifestations in GALE Deficiency: Extending the Spectrum Beyond Thrombocytopenia and Galactosemia<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-15T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">15 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 16. doi: 10.1007\/s10875-026-02018-w. Online ahead of print. NO ABSTRACT PMID:41986803 | DOI:10.1007\/s10875-026-02018-w<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/14\/low-igm-levels-in-adult-iei-classification-challenges-and-clinical-implications\/\">Low IgM Levels in Adult IEI: Classification Challenges and Clinical Implications<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-14T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">14 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 14. doi: 10.1007\/s10875-026-02017-x. Online ahead of print. NO ABSTRACT PMID:41979700 | DOI:10.1007\/s10875-026-02017-x<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/09\/first-case-of-tap1-deficiency-with-ebv-b-cell-lymphoma-treated-with-cellular-immunotherapy\/\">First Case of TAP1 Deficiency with EBV B-Cell Lymphoma Treated with Cellular Immunotherapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-09T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">9 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 9. doi: 10.1007\/s10875-026-01997-0. Online ahead of print. NO ABSTRACT PMID:41954665 | DOI:10.1007\/s10875-026-01997-0<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/09\/characteristics-of-mycobacterial-covid-19-and-talaromyces-marneffei-infections-in-patients-with-il12rb1-and-ifngr1-mutations-in-western-china\/\">Characteristics of Mycobacterial, COVID-19, and Talaromyces Marneffei Infections in Patients with IL12RB1 and IFNGR1 Mutations in Western China<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-09T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">9 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 10. doi: 10.1007\/s10875-026-01991-6. Online ahead of print. NO ABSTRACT PMID:41957131 | DOI:10.1007\/s10875-026-01991-6<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/06\/a-unique-ncf2-mutation-in-chronic-granulomatous-disease-clinical-and-computational-insights-into-nadph-oxidase-dysfunction\/\">A Unique NCF2 Mutation in Chronic Granulomatous Disease: Clinical and Computational Insights into NADPH Oxidase Dysfunction<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-06T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">6 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 6;46(1):39. doi: 10.1007\/s10875-026-02014-0. NO ABSTRACT PMID:41941091 | DOI:10.1007\/s10875-026-02014-0<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/06\/anifrolumab-to-treat-severe-hepatic-involvement-in-a-de-novo-ifih1-mutation\/\">Anifrolumab to Treat Severe Hepatic Involvement in a De Novo IFIH1 Mutation<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-06T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">6 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 6;46(1):41. doi: 10.1007\/s10875-026-01981-8. NO ABSTRACT PMID:41941034 | DOI:10.1007\/s10875-026-01981-8<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/01\/expanding-the-spectrum-of-src-family-kinase-related-autoinflammatory-diseases-monogenic-vasculitis-caused-by-germline-pathogenic-variants-in-hck-and-fgr\/\">Expanding the Spectrum of Src-Family Kinase-Related Autoinflammatory Diseases: Monogenic Vasculitis Caused By Germline Pathogenic Variants in HCK and FGR<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-04-01T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">1 de April de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Apr 1. doi: 10.1007\/s10875-026-01998-z. Online ahead of print. NO ABSTRACT PMID:41920357 | DOI:10.1007\/s10875-026-01998-z<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/31\/unclassified-inborn-errors-of-immunity-patients-without-any-pathogenic-variant-in-targeted-next-generation-sequencing-long-term-follow-up-and-whole-exome-sequencing-results\/\">Unclassified Inborn Errors of Immunity Patients without any Pathogenic Variant in Targeted Next-Generation Sequencing: Long-Term Follow-up and Whole Exome Sequencing Results<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-31T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">31 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 31. doi: 10.1007\/s10875-026-02007-z. Online ahead of print. NO ABSTRACT PMID:41917218 | DOI:10.1007\/s10875-026-02007-z<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/29\/continuous-infusion-of-the-cxcr4-antagonist-plerixafor-for-whim-syndrome\/\">Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-29T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">29 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 29. doi: 10.1007\/s10875-026-02010-4. Online ahead of print. NO ABSTRACT PMID:41904735 | DOI:10.1007\/s10875-026-02010-4<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/28\/optical-genome-mapping-for-the-identification-of-complex-structural-variants-in-hereditary-angioedema\/\">Optical Genome Mapping for the Identification of Complex Structural Variants in Hereditary Angioedema<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-28T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">28 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 28. doi: 10.1007\/s10875-026-02015-z. Online ahead of print. NO ABSTRACT PMID:41896320 | DOI:10.1007\/s10875-026-02015-z<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/28\/a-novel-phosphoglucomutase-3-gene-variant-causing-milder-phenotype-in-two-families\/\">A Novel Phosphoglucomutase-3 Gene Variant Causing Milder Phenotype in Two Families<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-28T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">28 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 29. doi: 10.1007\/s10875-026-02012-2. Online ahead of print. NO ABSTRACT PMID:41904308 | DOI:10.1007\/s10875-026-02012-2<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/28\/allogeneic-hematopoietic-cell-transplantation-for-congenital-athymia-a-nationwide-retrospective-study-in-japan\/\">Allogeneic Hematopoietic Cell Transplantation for Congenital Athymia: A Nationwide Retrospective Study in Japan<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-28T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">28 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 28. doi: 10.1007\/s10875-026-02008-y. Online ahead of print. ABSTRACT PURPOSE: Congenital athymia is a life-threatening condition characterized by thymic absence and profound T-cell immunodeficiency. Thymus implantation is the definitive treatment, but its availability is limited. This study aimed to evaluate the outcomes of hematopoietic cell transplantation (HCT) as an alternative therapy. &#8230; <a title=\"Allogeneic Hematopoietic Cell Transplantation for Congenital Athymia: A Nationwide Retrospective Study in Japan\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/28\/allogeneic-hematopoietic-cell-transplantation-for-congenital-athymia-a-nationwide-retrospective-study-in-japan\/\" aria-label=\"Read more about Allogeneic Hematopoietic Cell Transplantation for Congenital Athymia: A Nationwide Retrospective Study in Japan\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/26\/a-novel-pathogenic-variant-in-trac-gene-associated-with-scid-phenotype-expanding-the-genetic-and-clinical-spectrum\/\">A Novel Pathogenic Variant in TRAC Gene Associated with SCID Phenotype: Expanding the Genetic and Clinical Spectrum<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-26T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">26 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 26. doi: 10.1007\/s10875-026-02003-3. Online ahead of print. ABSTRACT PURPOSE: Pathogenic variants in the T-cell receptor alpha constant (TRAC) gene have been primarily associated with combined immunodeficiency (CID). To date, only five patients from three unrelated families harboring the same TRAC variant with a CID phenotype, and three patients carrying a &#8230; <a title=\"A Novel Pathogenic Variant in TRAC Gene Associated with SCID Phenotype: Expanding the Genetic and Clinical Spectrum\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/26\/a-novel-pathogenic-variant-in-trac-gene-associated-with-scid-phenotype-expanding-the-genetic-and-clinical-spectrum\/\" aria-label=\"Read more about A Novel Pathogenic Variant in TRAC Gene Associated with SCID Phenotype: Expanding the Genetic and Clinical Spectrum\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/26\/mechanistic-insights-into-immune-cell-dysregulation-mediated-by-novel-heterozygous-variants-in-card11-and-malt1\/\">Mechanistic Insights Into Immune Cell Dysregulation Mediated by Novel Heterozygous Variants in CARD11 and MALT1<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-26T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">26 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 26. doi: 10.1007\/s10875-026-02011-3. Online ahead of print. NO ABSTRACT PMID:41882201 | DOI:10.1007\/s10875-026-02011-3<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/24\/enhancing-clinical-workflow-efficiency-in-flow-cytometry-reporting-with-llms\/\">Enhancing Clinical Workflow Efficiency in Flow Cytometry Reporting with LLMs<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-24T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">24 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 24. doi: 10.1007\/s10875-026-02006-0. Online ahead of print. NO ABSTRACT PMID:41874828 | DOI:10.1007\/s10875-026-02006-0<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/23\/gata2-deficiency-syndrome-a-case-series-and-literature-review\/\">GATA2 Deficiency Syndrome: A Case Series and Literature Review<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-23T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">23 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 23. doi: 10.1007\/s10875-026-02013-1. Online ahead of print. NO ABSTRACT PMID:41870648 | DOI:10.1007\/s10875-026-02013-1<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/21\/excluded-gm-specific-igg-subclass-genes-in-health-and-disease-inborn-errors-of-immunity\/\">Excluded GM-specific IgG Subclass Genes in Health and Disease &#8211; Inborn Errors of Immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-21T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">21 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 21. doi: 10.1007\/s10875-026-02001-5. Online ahead of print. NO ABSTRACT PMID:41863686 | DOI:10.1007\/s10875-026-02001-5<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/21\/fostamatinib-dual-immunomodulation-in-post-haploidentical-hsct-autoimmune-cytopenia-and-autoimmune-hepatitis-a-case-report-and-review-of-literature\/\">Fostamatinib Dual Immunomodulation in Post-Haploidentical HSCT Autoimmune Cytopenia and Autoimmune Hepatitis: A Case Report and Review of Literature<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-21T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">21 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 21. doi: 10.1007\/s10875-026-02005-1. Online ahead of print. NO ABSTRACT PMID:41863683 | DOI:10.1007\/s10875-026-02005-1<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/21\/posttransplant-b-cell-development-and-function-in-patients-with-b-cell-positive-scid-caused-by-pathogenic-variants-in-il2rg-and-jak3\/\">Posttransplant B cell Development and Function in Patients with B cell Positive SCID Caused by Pathogenic Variants in IL2RG and JAK3<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-21T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">21 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 21. doi: 10.1007\/s10875-026-02004-2. Online ahead of print. NO ABSTRACT PMID:41863562 | DOI:10.1007\/s10875-026-02004-2<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/syndromic-inborn-errors-of-immunity-in-trec-newborn-screening-5-year-experience-from-the-german-screening-program\/\">Syndromic Inborn Errors of Immunity in TREC-Newborn Screening: 5-year Experience from the German Screening Program<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-14T11:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">14 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 14. doi: 10.1007\/s10875-026-01995-2. Online ahead of print. ABSTRACT TREC-NBS identifies patients with inborn errors of immunity (IEI) and syndromic features, but uncertainty remains regarding their immunological management. To address this, syndromic patients detected by TREC-NBS in Germany between August 2019 and April 2024 were systematically analyzed, including phenotype, treatment, and &#8230; <a title=\"Syndromic Inborn Errors of Immunity in TREC-Newborn Screening: 5-year Experience from the German Screening Program\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/syndromic-inborn-errors-of-immunity-in-trec-newborn-screening-5-year-experience-from-the-german-screening-program\/\" aria-label=\"Read more about Syndromic Inborn Errors of Immunity in TREC-Newborn Screening: 5-year Experience from the German Screening Program\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/07\/characterisation-of-a-leaky-splice-site-mutation-associated-with-phenotypic-diversity-in-two-unrelated-patients-with-arpc1b-deficiency\/\">Characterisation of a Leaky Splice-Site Mutation Associated with Phenotypic Diversity in Two Unrelated Patients with ARPC1B Deficiency<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-07T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">7 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 7. doi: 10.1007\/s10875-026-02002-4. Online ahead of print. NO ABSTRACT PMID:41793545 | DOI:10.1007\/s10875-026-02002-4<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/07\/prognostic-factors-for-sideroblastic-anemia-with-b-cell-immunodeficiency-periodic-fevers-and-developmental-delay-due-to-trnt1-gene-mutations-a-case-report-and-systematic-review\/\">Prognostic Factors for Sideroblastic Anemia with B-cell Immunodeficiency, Periodic Fevers, and Developmental Delay Due to TRNT1 Gene Mutations: A Case Report and Systematic Review<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-07T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">7 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 7. doi: 10.1007\/s10875-026-02000-6. Online ahead of print. NO ABSTRACT PMID:41795040 | DOI:10.1007\/s10875-026-02000-6<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/06\/the-experience-of-a-tertiary-reference-center-in-central-anatolia-with-children-carrying-zap-70-variants-including-two-novel-variants\/\">The Experience of a Tertiary Reference Center in Central Anatolia with Children Carrying ZAP-70 Variants, Including Two Novel Variants<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-06T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">6 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 6. doi: 10.1007\/s10875-026-01989-0. Online ahead of print. NO ABSTRACT PMID:41790376 | DOI:10.1007\/s10875-026-01989-0<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/04\/two-cases-of-clippers-like-syndrome-sharing-a-hypomorphic-unc13d-variant\/\">Two Cases of CLIPPERS-like Syndrome Sharing a Hypomorphic UNC13D Variant<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-04T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">4 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 4;46(1):23. doi: 10.1007\/s10875-026-01988-1. NO ABSTRACT PMID:41781714 | DOI:10.1007\/s10875-026-01988-1<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/02\/unraveling-bcr-repertoire-diversity-and-its-impact-on-glucocorticoid-therapy-in-pediatric-idiopathic-nephrotic-syndrome\/\">Unraveling BCR Repertoire Diversity and its Impact on Glucocorticoid Therapy in Pediatric Idiopathic Nephrotic Syndrome<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-03-02T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">2 de March de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Mar 2. doi: 10.1007\/s10875-026-01994-3. Online ahead of print. ABSTRACT AIM: Idiopathic nephrotic syndrome (INS) is the most common glomerular disease in children, but its underlying mechanisms remain unclear. Although glucocorticoids (GC) are the first-line treatment, approximately 10% of INS cases are steroid-resistant (SRNS), and 50% may progress to refractory nephrotic syndrome &#8230; <a title=\"Unraveling BCR Repertoire Diversity and its Impact on Glucocorticoid Therapy in Pediatric Idiopathic Nephrotic Syndrome\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/02\/unraveling-bcr-repertoire-diversity-and-its-impact-on-glucocorticoid-therapy-in-pediatric-idiopathic-nephrotic-syndrome\/\" aria-label=\"Read more about Unraveling BCR Repertoire Diversity and its Impact on Glucocorticoid Therapy in Pediatric Idiopathic Nephrotic Syndrome\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/28\/porto-sinusoidal-vascular-disease-is-associated-with-gastrointestinal-disorders-in-common-variable-immunodefiency\/\">Porto-sinusoidal Vascular Disease is Associated with Gastrointestinal Disorders in Common Variable Immunodefiency<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-28T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">28 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 28. doi: 10.1007\/s10875-026-01985-4. Online ahead of print. NO ABSTRACT PMID:41762359 | DOI:10.1007\/s10875-026-01985-4<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/26\/fatal-systemic-granulomatous-disease-associated-with-vaccine-derived-rubella-virus-in-aiolos-associated-immunodeficiency\/\">Fatal Systemic Granulomatous Disease Associated with Vaccine-Derived Rubella Virus in AIOLOS-Associated Immunodeficiency<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-26T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">26 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 26. doi: 10.1007\/s10875-026-01990-7. Online ahead of print. NO ABSTRACT PMID:41746515 | DOI:10.1007\/s10875-026-01990-7<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/26\/primary-immunodeficiency-diseases-with-bcg-induced-diseases-a-15-year-longitudinal-cohort-study\/\">Primary Immunodeficiency Diseases with BCG-Induced Diseases: A 15-Year Longitudinal Cohort Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-26T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">26 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 26. doi: 10.1007\/s10875-026-01996-1. Online ahead of print. NO ABSTRACT PMID:41748971 | DOI:10.1007\/s10875-026-01996-1<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/20\/a-cohort-study-of-38-classic-wiskott-aldrich-syndrome-cases-with-six-novel-mutations\/\">A Cohort Study of 38 Classic Wiskott-Aldrich Syndrome Cases with Six Novel Mutations<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-20T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">20 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 20. doi: 10.1007\/s10875-026-01986-3. Online ahead of print. NO ABSTRACT PMID:41718912 | DOI:10.1007\/s10875-026-01986-3<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/19\/tfrc-germline-variants-and-inborn-error-of-immunity-mechanistic-insights-into-iron-immune-crosstalk\/\">TFRC Germline Variants and Inborn Error of Immunity: Mechanistic Insights into Iron-Immune Crosstalk<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-19T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">19 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 20. doi: 10.1007\/s10875-026-01999-y. Online ahead of print. NO ABSTRACT PMID:41714512 | DOI:10.1007\/s10875-026-01999-y<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/17\/goods-syndrome-mirrors-a-combined-immunodeficiency-with-anti-cytokine-antibodies-in-the-total-absence-of-b-cells\/\">Good&#8217;s Syndrome Mirrors a Combined Immunodeficiency with Anti-Cytokine Antibodies in the Total Absence of B Cells<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-17T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">17 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 17. doi: 10.1007\/s10875-026-01992-5. Online ahead of print. NO ABSTRACT PMID:41701387 | DOI:10.1007\/s10875-026-01992-5<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/13\/spectrum-of-primary-immune-regulatory-disorders-in-children-in-a-highly-consanguineous-population-report-from-a-national-registry\/\">Spectrum of Primary Immune Regulatory Disorders in Children in a Highly Consanguineous Population: Report from a National Registry<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-13T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">13 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 14. doi: 10.1007\/s10875-026-01993-4. Online ahead of print. NO ABSTRACT PMID:41688586 | DOI:10.1007\/s10875-026-01993-4<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/was-protein-deficiency-disrupts-memory-b-cell-formation-during-acute-lcmv-infection\/\">WAS Protein Deficiency Disrupts Memory B Cell Formation During Acute LCMV Infection<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-11T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">11 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 11. doi: 10.1007\/s10875-026-01984-5. Online ahead of print. ABSTRACT Wiskott-Aldrich syndrome (WAS) is a rare x-linked monogenic immunodeficiency disease, caused by the mutation of WAS gene encoding WAS protein (WASp). Previous findings in WAS patients show B cell perturbations in the periphery, characterized by diminished B-cell numbers and phenotype abnormalities, including &#8230; <a title=\"WAS Protein Deficiency Disrupts Memory B Cell Formation During Acute LCMV Infection\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/was-protein-deficiency-disrupts-memory-b-cell-formation-during-acute-lcmv-infection\/\" aria-label=\"Read more about WAS Protein Deficiency Disrupts Memory B Cell Formation During Acute LCMV Infection\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/10\/transcatheter-arterial-approach-for-refractory-liver-abscesses-in-chronic-granulomatous-disease-a-case-series\/\">Transcatheter Arterial Approach for Refractory Liver Abscesses in Chronic Granulomatous Disease: A Case Series<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-10T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">10 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 10;46(1):16. doi: 10.1007\/s10875-025-01976-x. NO ABSTRACT PMID:41665758 | DOI:10.1007\/s10875-025-01976-x<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/07\/pediatric-ipex-associated-dermatitis-responds-to-dupilumab-evidence-from-skin-transcriptomics-and-immune-profiling\/\">Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-07T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">7 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 7. doi: 10.1007\/s10875-025-01979-8. Online ahead of print. ABSTRACT PURPOSE: Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked (IPEX) syndrome is a rare autoimmune disorder caused by mutations in the FOXP3 gene. Patients with IPEX frequently present with severe dermatitis, diabetes, and enteropathy. This study explores the efficacy of Dupilumab (an anti-IL-4R\u03b1 monoclonal antibody) &#8230; <a title=\"Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/07\/pediatric-ipex-associated-dermatitis-responds-to-dupilumab-evidence-from-skin-transcriptomics-and-immune-profiling\/\" aria-label=\"Read more about Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/03\/%ce%b1%ce%b2t-cd19-depleted-allogeneic-stem-cell-transplantation-in-adults-with-inborn-errors-of-immunity\/\">\u03b1\u03b2T\/CD19-depleted Allogeneic Stem Cell Transplantation in Adults with Inborn Errors of Immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-03T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">3 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 3. doi: 10.1007\/s10875-025-01978-9. Online ahead of print. ABSTRACT PURPOSE: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is successful in pediatric patients with inborn errors of immunity (IEI), but its use in adults is complicated by pre-existing organ damage and increased risk of treatment-related mortality. Ex vivo graft engineering using \u03b1\u03b2TCR\/CD19 depletion &#8230; <a title=\"\u03b1\u03b2T\/CD19-depleted Allogeneic Stem Cell Transplantation in Adults with Inborn Errors of Immunity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/03\/%ce%b1%ce%b2t-cd19-depleted-allogeneic-stem-cell-transplantation-in-adults-with-inborn-errors-of-immunity\/\" aria-label=\"Read more about \u03b1\u03b2T\/CD19-depleted Allogeneic Stem Cell Transplantation in Adults with Inborn Errors of Immunity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/02\/follicular-helper-t-cells-and-b-cell-maturation-in-patients-with-22q11-2-deletion-syndrome-and-recurrent-infections\/\">Follicular Helper T Cells and B Cell Maturation in Patients with 22q11.2 Deletion Syndrome and Recurrent Infections<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-02T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">2 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 3. doi: 10.1007\/s10875-026-01987-2. Online ahead of print. ABSTRACT PURPOSE: 22q11.2 Deletion Syndrome has been primarily described as a disorder of T cell production secondary to thymic hypoplasia. However, there is great complexity in the clinical picture with infections, autoimmunity, and inflammation occurring. Emerging evidence suggests that qualitative T cell dysfunction &#8230; <a title=\"Follicular Helper T Cells and B Cell Maturation in Patients with 22q11.2 Deletion Syndrome and Recurrent Infections\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/02\/follicular-helper-t-cells-and-b-cell-maturation-in-patients-with-22q11-2-deletion-syndrome-and-recurrent-infections\/\" aria-label=\"Read more about Follicular Helper T Cells and B Cell Maturation in Patients with 22q11.2 Deletion Syndrome and Recurrent Infections\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/02\/correction-to-a-multicentric-clinical-study-to-evaluate-pharmacokinetics-efficacy-and-safety-of-immune-globulin-subcutaneous-20-weekly-biweekly-dosing-in-treatment-experienced-patients-and-loading\/\">Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly\/Biweekly Dosing in Treatment-Experienced Patients and Loading\/Weekly Maintenance Dosing in Treatment-Na\u00efve Patients with Primary Immunodeficiency<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-02T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">2 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 2;46(1):15. doi: 10.1007\/s10875-026-01983-6. NO ABSTRACT PMID:41627598 | DOI:10.1007\/s10875-026-01983-6<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/02\/partial-purine-nucleoside-phosphorylase-deficiency-an-unexpected-diagnosis-in-an-adult-patient\/\">Partial Purine Nucleoside Phosphorylase Deficiency: an Unexpected Diagnosis in an Adult Patient<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-02T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">2 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 2;46(1):14. doi: 10.1007\/s10875-025-01941-8. NO ABSTRACT PMID:41627577 | DOI:10.1007\/s10875-025-01941-8<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/02\/net-biomarkers-in-covid-19-and-post-covid-syndrome-a-comprehensive-analysis\/\">NET Biomarkers in COVID-19 and Post-COVID Syndrome: a Comprehensive Analysis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-02-02T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">2 de February de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Feb 2. doi: 10.1007\/s10875-026-01980-9. Online ahead of print. NO ABSTRACT PMID:41627524 | DOI:10.1007\/s10875-026-01980-9<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/27\/a-case-based-literature-review-of-rela-associated-inflammatory-diseases\/\">A Case-Based Literature Review of RELA Associated Inflammatory Diseases<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-27T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">27 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Jan 27. doi: 10.1007\/s10875-025-01968-x. Online ahead of print. ABSTRACT Beh\u00e7et&#8217;s disease (BD) is a chronic inflammatory disorder characterized by recurrent oral aphthous ulcers, genital ulcers, skin lesions, and uveitis. Recent genetic studies have identified monogenic diseases with phenotypes resembling BD, including RELA-associated inflammatory disease (RAID), Haploinsufficiency of A20 (HA20), and otulipenia. &#8230; <a title=\"A Case-Based Literature Review of RELA Associated Inflammatory Diseases\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/27\/a-case-based-literature-review-of-rela-associated-inflammatory-diseases\/\" aria-label=\"Read more about A Case-Based Literature Review of RELA Associated Inflammatory Diseases\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/21\/correction-to-an-international-survey-of-allogeneic-hematopoietic-cell-transplantation-for-x-linked-agammaglobulinemia\/\">Correction to: An international survey of allogeneic hematopoietic cell transplantation for X-linked agammaglobulinemia<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-21T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">21 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Jan 21;46(1):11. doi: 10.1007\/s10875-026-01982-7. NO ABSTRACT PMID:41563625 | DOI:10.1007\/s10875-026-01982-7<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/antibody-deficiency-in-xeroderma-pigmentosum\/\">Antibody Deficiency in Xeroderma Pigmentosum<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-10T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">10 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Jan 10;46(1):4. doi: 10.1007\/s10875-025-01967-y. ABSTRACT We describe a 3-year-old patient with xeroderma pigmentosum (XP) and genetically confirmed XPA deficiency who presented with recurrent infections in early childhood. Immunological assessment revealed mild hypogammaglobulinemia with IgG2 and IgG3 subclass deficiencies, as well as impaired humoral immunity demonstrated by a reduced antibody response to &#8230; <a title=\"Antibody Deficiency in Xeroderma Pigmentosum\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/10\/antibody-deficiency-in-xeroderma-pigmentosum\/\" aria-label=\"Read more about Antibody Deficiency in Xeroderma Pigmentosum\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/06\/multidimensional-assessment-of-patient-reported-outcomes-in-a-multicenter-cohort-of-inborn-errors-of-immunity\/\">Multidimensional Assessment of Patient-Reported-Outcomes in a Multicenter Cohort of Inborn Errors of Immunity<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-06T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">6 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Jan 6. doi: 10.1007\/s10875-025-01972-1. Online ahead of print. ABSTRACT Patient-reported outcomes are critical to multidisciplinary, patient-centred approaches in diseases requiring lifelong management. Among inborn errors of immunity (IEIs), reports on this subject are typically limited to specific diagnostic subgroups or focus narrowly on the route of immunoglobulin replacement therapy (IgRT), offering &#8230; <a title=\"Multidimensional Assessment of Patient-Reported-Outcomes in a Multicenter Cohort of Inborn Errors of Immunity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/06\/multidimensional-assessment-of-patient-reported-outcomes-in-a-multicenter-cohort-of-inborn-errors-of-immunity\/\" aria-label=\"Read more about Multidimensional Assessment of Patient-Reported-Outcomes in a Multicenter Cohort of Inborn Errors of Immunity\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/03\/tnfrsf13b-variant-induced-taci-dysregulation-underlies-caebv-pathogenesis\/\">TNFRSF13B Variant-Induced TACI Dysregulation Underlies CAEBV Pathogenesis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2026-01-03T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">3 de January de 2026<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2026 Jan 2. doi: 10.1007\/s10875-025-01973-0. Online ahead of print. ABSTRACT The tumor necrosis factor (TNF) receptor superfamily member, transmembrane activator and CAML interactor (TACI) encoded by TNFRSF13B, are extensively involved in immune responses. In our previous work, TNFRSF13B exon 2 variants were recurrently identified in chronic active Epstein-Barr virus disease (CAEBV). Here &#8230; <a title=\"TNFRSF13B Variant-Induced TACI Dysregulation Underlies CAEBV Pathogenesis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/03\/tnfrsf13b-variant-induced-taci-dysregulation-underlies-caebv-pathogenesis\/\" aria-label=\"Read more about TNFRSF13B Variant-Induced TACI Dysregulation Underlies CAEBV Pathogenesis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/27\/immune-signatures-of-smoking-cytokine-and-immunoglobulin-dysregulation-and-partial-reversibility-in-a-population-based-study\/\">Immune Signatures of Smoking: Cytokine and Immunoglobulin Dysregulation and Partial Reversibility in a Population-Based Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-27T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">27 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Dec 27. doi: 10.1007\/s10875-025-01975-y. Online ahead of print. NO ABSTRACT PMID:41454991 | DOI:10.1007\/s10875-025-01975-y<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/26\/the-distinct-monocyte-subsets-and-intercellular-communication-in-primary-sjogrens-syndrome-revealed-by-single-cell-rna-sequencing\/\">The Distinct Monocyte Subsets and Intercellular Communication in Primary Sj\u00f6gren&#8217;s Syndrome Revealed by Single-Cell RNA Sequencing<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-26T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">26 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Dec 27. doi: 10.1007\/s10875-025-01974-z. Online ahead of print. ABSTRACT OBJECTIVE: The presence of unique monocyte subsets and sub-populations plays a significant role in the onset and progression of rheumatic diseases. This study aimed to characterize variations in monocyte subsets and sub-populations and functional roles in patients with primary Sj\u00f6gren&#8217;s syndrome (pSS) &#8230; <a title=\"The Distinct Monocyte Subsets and Intercellular Communication in Primary Sj\u00f6gren&#8217;s Syndrome Revealed by Single-Cell RNA Sequencing\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/26\/the-distinct-monocyte-subsets-and-intercellular-communication-in-primary-sjogrens-syndrome-revealed-by-single-cell-rna-sequencing\/\" aria-label=\"Read more about The Distinct Monocyte Subsets and Intercellular Communication in Primary Sj\u00f6gren&#8217;s Syndrome Revealed by Single-Cell RNA Sequencing\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/26\/age-related-patterns-of-type-ii-interferon-immunity-implications-for-intramacrophagic-infections-and-msmd-diagnosis-during-childhood\/\">Age-Related Patterns of Type II Interferon Immunity: Implications for Intramacrophagic Infections and MSMD Diagnosis During Childhood<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-26T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">26 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Dec 26. doi: 10.1007\/s10875-025-01955-2. Online ahead of print. ABSTRACT Type II interferon (IFN) immunity is crucial for controlling intramacrophagic infections, driven by the interaction between innate immunity (macrophage-derived IL-12) and adaptive immunity (Th-derived IFN-\u03b3). This study examines the maturation of type II IFN immunity in 55 healthy children (ages 1-18) to &#8230; <a title=\"Age-Related Patterns of Type II Interferon Immunity: Implications for Intramacrophagic Infections and MSMD Diagnosis During Childhood\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/26\/age-related-patterns-of-type-ii-interferon-immunity-implications-for-intramacrophagic-infections-and-msmd-diagnosis-during-childhood\/\" aria-label=\"Read more about Age-Related Patterns of Type II Interferon Immunity: Implications for Intramacrophagic Infections and MSMD Diagnosis During Childhood\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/23\/signatures-of-trained-immunity-following-mrna-vaccination-differences-between-mrna-1273-and-bnt162b2\/\">Signatures of Trained Immunity Following mRNA Vaccination: Differences Between mRNA-1273 and BNT162b2<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-23T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">23 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Dec 24. doi: 10.1007\/s10875-025-01977-w. Online ahead of print. ABSTRACT Trained immunity, a de-facto innate immune memory, has been extensively studied in response to live-attenuated vaccines, but its presence following the new COVID-19 vaccines has not yet been fully elucidated. In this study, we investigate markers of trained immunity in individuals vaccinated &#8230; <a title=\"Signatures of Trained Immunity Following mRNA Vaccination: Differences Between mRNA-1273 and BNT162b2\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/23\/signatures-of-trained-immunity-following-mrna-vaccination-differences-between-mrna-1273-and-bnt162b2\/\" aria-label=\"Read more about Signatures of Trained Immunity Following mRNA Vaccination: Differences Between mRNA-1273 and BNT162b2\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/14\/rna-sequencing-addresses-a-5-utr-variant-leading-to-x-linked-agammaglobulinemia-and-broader-immune-dysregulation\/\">RNA Sequencing Addresses a 5&#8242; UTR Variant Leading to X-Linked Agammaglobulinemia and Broader Immune Dysregulation<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-14T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">14 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Dec 13. doi: 10.1007\/s10875-025-01971-2. Online ahead of print. NO ABSTRACT PMID:41390883 | DOI:10.1007\/s10875-025-01971-2<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/12\/exploring-the-pathogens-in-primary-predominantly-antibody-deficiencies-of-unknown-genetic-origin\/\">Exploring the Pathogens in Primary Predominantly Antibody Deficiencies of Unknown Genetic Origin<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-12T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">12 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Dec 12. doi: 10.1007\/s10875-025-01970-3. Online ahead of print. ABSTRACT INTRODUCTION: Primary &#8216;predominantly antibody deficiencies&#8217; (PADs) are rare disorders characterized by increased susceptibility to infections, autoimmunity, allergies, and malignancies. Their low prevalence and heterogeneity often delay diagnosis, increasing morbidity and mortality. This study identifies infection patterns in PAD patients and analyzes predictors &#8230; <a title=\"Exploring the Pathogens in Primary Predominantly Antibody Deficiencies of Unknown Genetic Origin\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/12\/exploring-the-pathogens-in-primary-predominantly-antibody-deficiencies-of-unknown-genetic-origin\/\" aria-label=\"Read more about Exploring the Pathogens in Primary Predominantly Antibody Deficiencies of Unknown Genetic Origin\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/10\/exaggerated-ifn-i-response-in-long-covid-pbmcs-following-exposure-to-viral-mimics\/\">Exaggerated IFN-I Response in Long COVID PBMCs Following Exposure to Viral Mimics<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-12-10T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">10 de December de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Dec 10. doi: 10.1007\/s10875-025-01969-w. Online ahead of print. ABSTRACT PURPOSE: Long COVID (LC) is a long-term debilitating disease of which the exact pathophysiology is unknown. A dysregulated immune response resulting in hyperresponsive immune cells is hypothesized as a key mechanism in the development of LC. Several studies suggest that acute infections &#8230; <a title=\"Exaggerated IFN-I Response in Long COVID PBMCs Following Exposure to Viral Mimics\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/10\/exaggerated-ifn-i-response-in-long-covid-pbmcs-following-exposure-to-viral-mimics\/\" aria-label=\"Read more about Exaggerated IFN-I Response in Long COVID PBMCs Following Exposure to Viral Mimics\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/28\/iga-and-igm-enriched-immunoglobulins-in-primary-immunodeficiencies-a-pilot-study\/\">IgA and IgM-enriched Immunoglobulins in Primary Immunodeficiencies: a Pilot Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-28T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">28 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 28. doi: 10.1007\/s10875-025-01966-z. Online ahead of print. ABSTRACT PURPOSE: Despite well-conducted replacement therapy with polyvalent immunoglobulins (IgRT), some patients with primary immunodeficiencies (PID) continue to experience recurrent or chronic infections. IgA and IgM, essential for mucosal and complement-mediated immunity, are absent or minimal in standard immunoglobulin products. The aim of &#8230; <a title=\"IgA and IgM-enriched Immunoglobulins in Primary Immunodeficiencies: a Pilot Study\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/28\/iga-and-igm-enriched-immunoglobulins-in-primary-immunodeficiencies-a-pilot-study\/\" aria-label=\"Read more about IgA and IgM-enriched Immunoglobulins in Primary Immunodeficiencies: a Pilot Study\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/28\/exosomes-in-autoimmunity-mediators-of-autoantigen-presentation-and-targets-for-therapeutic-intervention-in-autoimmune-diseases\/\">Exosomes in Autoimmunity: Mediators of Autoantigen Presentation and Targets for Therapeutic Intervention in Autoimmune Diseases<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-28T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">28 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 28. doi: 10.1007\/s10875-025-01965-0. Online ahead of print. ABSTRACT Exosomes, as integral mediators of cellular communication, have emerged as crucial players in the pathogenesis and potential treatment of autoimmune diseases. This review explores the dual role of exosomes in mediating autoantigen presentation and their impact on immune dysregulation. Exosomes, by virtue &#8230; <a title=\"Exosomes in Autoimmunity: Mediators of Autoantigen Presentation and Targets for Therapeutic Intervention in Autoimmune Diseases\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/28\/exosomes-in-autoimmunity-mediators-of-autoantigen-presentation-and-targets-for-therapeutic-intervention-in-autoimmune-diseases\/\" aria-label=\"Read more about Exosomes in Autoimmunity: Mediators of Autoantigen Presentation and Targets for Therapeutic Intervention in Autoimmune Diseases\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/26\/tap-i-deficiency-presenting-with-chronic-granulomatous-rubella-virus-driven-cutaneous-ulceration-a-case-report-and-scoping-literature-review\/\">TAP-I Deficiency Presenting With Chronic Granulomatous Rubella Virus-Driven Cutaneous Ulceration: A Case Report and Scoping Literature Review<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-26T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">26 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 27. doi: 10.1007\/s10875-025-01919-6. Online ahead of print. ABSTRACT Autosomal recessive mutations in TAP1, TAP2, TAPBP, or B2M, are associated with major histocompatibility complex (MHC) class I deficiency. Individuals may present with granulomatous skin ulceration, but the underlying antigenic triggers remain largely unknown. We identified TAP1 deficiency in a 32-year-old female &#8230; <a title=\"TAP-I Deficiency Presenting With Chronic Granulomatous Rubella Virus-Driven Cutaneous Ulceration: A Case Report and Scoping Literature Review\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/26\/tap-i-deficiency-presenting-with-chronic-granulomatous-rubella-virus-driven-cutaneous-ulceration-a-case-report-and-scoping-literature-review\/\" aria-label=\"Read more about TAP-I Deficiency Presenting With Chronic Granulomatous Rubella Virus-Driven Cutaneous Ulceration: A Case Report and Scoping Literature Review\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/cxcl13-as-a-biomarker-of-complex-common-variable-immunodeficiency\/\">CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-25T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">25 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 25;45(1):168. doi: 10.1007\/s10875-025-01963-2. ABSTRACT BACKGROUND: Common Variable Immunodeficiency (CVID) is a group of heterogeneous disorders with common denominators of impaired antibody production and function, and recurrent infections. Currently, prognostic biomarkers for CVID are limited. CXCL13 is a critical regulator of germinal centre responses and antibody production, with T follicular helper &#8230; <a title=\"CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/cxcl13-as-a-biomarker-of-complex-common-variable-immunodeficiency\/\" aria-label=\"Read more about CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/clinical-and-immunological-impact-of-jak-inhibition-in-concurrent-down-syndrome-and-stat1-gain-of-function\/\">Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-25T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">25 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 25;45(1):167. doi: 10.1007\/s10875-025-01957-0. ABSTRACT Down syndrome (DS) and STAT1 gain-of-function (GOF) share clinical and molecular features, including persistent inflammation. We aimed to investigate whether the coexistence of DS and a STAT1 GOF mutation in a patient synergistically enhances interferon (IFN) signaling and exacerbates inflammatory responses, posing additional management challenges. Two &#8230; <a title=\"Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/clinical-and-immunological-impact-of-jak-inhibition-in-concurrent-down-syndrome-and-stat1-gain-of-function\/\" aria-label=\"Read more about Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/natural-history-of-swiss-infants-with-non-scid-t-cell-lymphopenia-detected-by-newborn-screening-a-cohort-study\/\">Natural History of Swiss Infants with Non-SCID T-cell Lymphopenia Detected by Newborn Screening: A Cohort Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-25T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">25 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 25;45(1):166. doi: 10.1007\/s10875-025-01945-4. ABSTRACT BACKGROUND: Newborn screening (NBS) by quantification of T-cell receptor excision circles (TREC) identifies a considerable number of infants with T-cell lymphopenia (TCL) other than severe combined immunodeficiency (SCID). While some of these children have well-defined inborn errors of immunity (IEI), many lack a clear genetic diagnosis, &#8230; <a title=\"Natural History of Swiss Infants with Non-SCID T-cell Lymphopenia Detected by Newborn Screening: A Cohort Study\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/natural-history-of-swiss-infants-with-non-scid-t-cell-lymphopenia-detected-by-newborn-screening-a-cohort-study\/\" aria-label=\"Read more about Natural History of Swiss Infants with Non-SCID T-cell Lymphopenia Detected by Newborn Screening: A Cohort Study\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/monocyte-macrophage-derived-nlrp3-promotes-the-onset-and-progression-of-ankylosing-spondylitis-via-the-nod-like-receptor-pathway\/\">Monocyte\/macrophage-derived NLRP3 Promotes the Onset and Progression of Ankylosing Spondylitis Via the NOD-like Receptor Pathway<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-25T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">25 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 26. doi: 10.1007\/s10875-025-01961-4. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVES: Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disease primarily affecting the axial skeleton. Despite significant advances, its pathogenic mechanisms remain unclear, posing challenges to early diagnosis and effective treatment. This study aims to elucidate the pathogenic pathways of &#8230; <a title=\"Monocyte\/macrophage-derived NLRP3 Promotes the Onset and Progression of Ankylosing Spondylitis Via the NOD-like Receptor Pathway\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/25\/monocyte-macrophage-derived-nlrp3-promotes-the-onset-and-progression-of-ankylosing-spondylitis-via-the-nod-like-receptor-pathway\/\" aria-label=\"Read more about Monocyte\/macrophage-derived NLRP3 Promotes the Onset and Progression of Ankylosing Spondylitis Via the NOD-like Receptor Pathway\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/whole-genome-sequencing-in-25-families-with-suspected-inborn-errors-of-immunity-diagnostic-yield-and-clinical-relevance-of-genome-wide-analysis\/\">Whole Genome Sequencing in 25 Families with Suspected Inborn Errors of Immunity: Diagnostic Yield and Clinical Relevance of Genome-wide Analysis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-22T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">22 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 23. doi: 10.1007\/s10875-025-01947-2. Online ahead of print. ABSTRACT INTRODUCTION: Inborn errors of immunity (IEIs) constitute a diverse group of more than 500 disorders resulting from pathogenic variants in over 500 causative genes, with most being monogenic diseases. The use of exome sequencing based on next-generation sequencing technologies has significantly advanced &#8230; <a title=\"Whole Genome Sequencing in 25 Families with Suspected Inborn Errors of Immunity: Diagnostic Yield and Clinical Relevance of Genome-wide Analysis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/whole-genome-sequencing-in-25-families-with-suspected-inborn-errors-of-immunity-diagnostic-yield-and-clinical-relevance-of-genome-wide-analysis\/\" aria-label=\"Read more about Whole Genome Sequencing in 25 Families with Suspected Inborn Errors of Immunity: Diagnostic Yield and Clinical Relevance of Genome-wide Analysis\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/17\/stat-1-gain-of-function-cmc-remission-of-oral-candidiasis-during-pd-1-inhibitor-treatment-of-oral-cancer\/\">STAT-1 gain-of-function CMC: Remission of Oral Candidiasis during PD-1 Inhibitor Treatment of Oral Cancer<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-17T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">17 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 18;45(1):164. doi: 10.1007\/s10875-025-01948-1. NO ABSTRACT PMID:41249721 | DOI:10.1007\/s10875-025-01948-1<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/17\/the-spectrum-of-bacterial-infection-in-a-large-cohort-of-chinese-pediatric-patients-with-inborn-errors-of-immunity-a-nine-year-retrospective-single-center-study\/\">The Spectrum of Bacterial Infection in a Large Cohort of Chinese Pediatric Patients with Inborn Errors of Immunity: A Nine-year, Retrospective, Single-center Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-17T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">17 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 18;45(1):163. doi: 10.1007\/s10875-025-01964-1. ABSTRACT PURPOSE: This study aimed to investigate the spectrum of bacterial infections in children with inborn error of immunity (IEIs). METHODS: Pediatric patients with IEIs and positive for bacteria considered to be pathogenic were included in this retrospective study. RESULTS: In this study, 1811 medical records of &#8230; <a title=\"The Spectrum of Bacterial Infection in a Large Cohort of Chinese Pediatric Patients with Inborn Errors of Immunity: A Nine-year, Retrospective, Single-center Study\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/17\/the-spectrum-of-bacterial-infection-in-a-large-cohort-of-chinese-pediatric-patients-with-inborn-errors-of-immunity-a-nine-year-retrospective-single-center-study\/\" aria-label=\"Read more about The Spectrum of Bacterial Infection in a Large Cohort of Chinese Pediatric Patients with Inborn Errors of Immunity: A Nine-year, Retrospective, Single-center Study\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/17\/evaluating-pediatric-reference-ranges-for-extended-immunophenotyping-from-a-finnish-cohort-against-published-references\/\">Evaluating Pediatric Reference Ranges for Extended Immunophenotyping from a Finnish Cohort against Published References<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-17T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">17 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 18;45(1):162. doi: 10.1007\/s10875-025-01959-y. ABSTRACT Flow cytometric immunophenotyping of lymphocytes and dendritic cells, and functional lymphocyte mitogen response tests are used in the diagnostics of inborn errors of immunity (IEI), especially in pediatrics. These routinely used tests lack sufficient age-matched reference values in children. We established reference values for lymphocyte and &#8230; <a title=\"Evaluating Pediatric Reference Ranges for Extended Immunophenotyping from a Finnish Cohort against Published References\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/17\/evaluating-pediatric-reference-ranges-for-extended-immunophenotyping-from-a-finnish-cohort-against-published-references\/\" aria-label=\"Read more about Evaluating Pediatric Reference Ranges for Extended Immunophenotyping from a Finnish Cohort against Published References\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/17\/neurological-phenotypes-of-socs1-haploinsufficiency-insights-from-functional-and-histological-investigations\/\">Neurological Phenotypes of SOCS1 Haploinsufficiency: Insights from Functional and Histological Investigations<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-17T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">17 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 18;45(1):165. doi: 10.1007\/s10875-025-01958-z. ABSTRACT Suppressor of cytokine signaling 1 (SOCS1) haploinsufficiency is a recently described inborn error of immunity characterized by autoimmunity, inflammation, lymphoproliferation, and increased infection susceptibility. SOCS1, a negative regulator of cytokine signaling via the JAK\/STAT pathway, explains the condition&#8217;s broad phenotypic variability. Single nucleotide polymorphisms in SOCS1 &#8230; <a title=\"Neurological Phenotypes of SOCS1 Haploinsufficiency: Insights from Functional and Histological Investigations\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/17\/neurological-phenotypes-of-socs1-haploinsufficiency-insights-from-functional-and-histological-investigations\/\" aria-label=\"Read more about Neurological Phenotypes of SOCS1 Haploinsufficiency: Insights from Functional and Histological Investigations\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/15\/s100a4-induces-neutrophilic-inflammation-in-chronic-rhinosinusitis-with-nasal-polyps-via-tlr4-pathway\/\">S100A4 Induces Neutrophilic Inflammation in Chronic Rhinosinusitis with Nasal Polyps via TLR4 Pathway<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-15T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">15 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 15;45(1):160. doi: 10.1007\/s10875-025-01953-4. ABSTRACT BACKGROUND: Treating neutrophilic inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP) remains a challenge. Managing excessive infiltration and activation of neutrophils in tissues is important for improving CRSwNP outcomes. S100A4, a calcium-binding protein, regulates cell migration, chemotaxis and tissue fibrosis. In this study, we sought to &#8230; <a title=\"S100A4 Induces Neutrophilic Inflammation in Chronic Rhinosinusitis with Nasal Polyps via TLR4 Pathway\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/15\/s100a4-induces-neutrophilic-inflammation-in-chronic-rhinosinusitis-with-nasal-polyps-via-tlr4-pathway\/\" aria-label=\"Read more about S100A4 Induces Neutrophilic Inflammation in Chronic Rhinosinusitis with Nasal Polyps via TLR4 Pathway\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/15\/bronchiectasis-low-igg-levels-and-lack-of-vaccination-are-risk-factors-for-covid-19-hospitalization-in-x-linked-agammaglobulinemia-a-retrospective-multicenter-study\/\">Bronchiectasis, Low IgG Levels and Lack of Vaccination are Risk Factors for Covid-19 Hospitalization in X-linked Agammaglobulinemia &#8211; A Retrospective Multicenter Study<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-15T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">15 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 15;45(1):161. doi: 10.1007\/s10875-025-01962-3. ABSTRACT X-linked agammaglobulinemia (XLA) is caused by loss-of-function variants in Bruton&#8217;s tyrosine kinase, leading to absence of circulating B lymphocytes and inability to produce antibodies. Despite the fear that patients with XLA would be at high risk for severe infection when the novel virus SARS-CoV-2 emerged in &#8230; <a title=\"Bronchiectasis, Low IgG Levels and Lack of Vaccination are Risk Factors for Covid-19 Hospitalization in X-linked Agammaglobulinemia &#8211; A Retrospective Multicenter Study\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/15\/bronchiectasis-low-igg-levels-and-lack-of-vaccination-are-risk-factors-for-covid-19-hospitalization-in-x-linked-agammaglobulinemia-a-retrospective-multicenter-study\/\" aria-label=\"Read more about Bronchiectasis, Low IgG Levels and Lack of Vaccination are Risk Factors for Covid-19 Hospitalization in X-linked Agammaglobulinemia &#8211; A Retrospective Multicenter Study\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/11\/a-new-variant-in-ctla4-highlights-the-heterogeneous-phenotype-of-ctla4-haploinsufficiency\/\">A New Variant in CTLA4 Highlights the Heterogeneous Phenotype of CTLA4 Haploinsufficiency<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-11T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">11 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 12;45(1):159. doi: 10.1007\/s10875-025-01960-5. ABSTRACT Haploinsufficiency of cytotoxic T-lymphocyte associated protein 4 (CTLA4), a known cause of inborn errors of immunity, can lead to autoimmunity, inflammation, neoplasia and infections. A previously undescribed CTLA4 variant was identified in a patient who presented with life-threatening cutaneous infection caused by Pseudomonas aeruginosa, severe VZV &#8230; <a title=\"A New Variant in CTLA4 Highlights the Heterogeneous Phenotype of CTLA4 Haploinsufficiency\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/11\/a-new-variant-in-ctla4-highlights-the-heterogeneous-phenotype-of-ctla4-haploinsufficiency\/\" aria-label=\"Read more about A New Variant in CTLA4 Highlights the Heterogeneous Phenotype of CTLA4 Haploinsufficiency\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/11\/a-multicentric-clinical-study-to-evaluate-pharmacokinetics-efficacy-and-safety-of-immune-globulin-subcutaneous-20-weekly-biweekly-dosing-in-treatment-experienced-patients-and-loading-weekly-maintena\/\">A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly\/Biweekly Dosing in Treatment-Experienced Patients and Loading\/Weekly Maintenance Dosing in Treatment-Na\u00efve Patients with Primary Immunodeficiency<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-11T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">11 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 12;45(1):158. doi: 10.1007\/s10875-025-01952-5. ABSTRACT Intravenous immunoglobulin (IVIG) therapy is a well-documented and effective treatment for primary immunodeficiencies (PI). Subcutaneous immunoglobulins (SCIG) have emerged as an effective alternative for some patients that offers additional flexibility.Currently, caprylate\/chromatography purified IGSC (human) 20% is approved to treat PI in North America and many countries &#8230; <a title=\"A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly\/Biweekly Dosing in Treatment-Experienced Patients and Loading\/Weekly Maintenance Dosing in Treatment-Na\u00efve Patients with Primary Immunodeficiency\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/11\/a-multicentric-clinical-study-to-evaluate-pharmacokinetics-efficacy-and-safety-of-immune-globulin-subcutaneous-20-weekly-biweekly-dosing-in-treatment-experienced-patients-and-loading-weekly-maintena\/\" aria-label=\"Read more about A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly\/Biweekly Dosing in Treatment-Experienced Patients and Loading\/Weekly Maintenance Dosing in Treatment-Na\u00efve Patients with Primary Immunodeficiency\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/09\/impact-of-immune-cells-on-iga-vasculitis-via-metabolites-and-inflammatory-cytokines\/\">Impact of Immune Cells on IgA Vasculitis via Metabolites and Inflammatory Cytokines<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-09T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">9 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 10;45(1):157. doi: 10.1007\/s10875-025-01946-3. ABSTRACT BACKGROUND: IgA vasculitis (IgAV) is an autoimmune disorder characterized by inflammation of the small blood vessels. The pathogenesis of IgAV is believed to involve a complex interplay between immune cells, metabolites, and inflammatory cytokines (ICs). METHODS: We performed two-sample Mendelian randomization (MR) analysis to examine the &#8230; <a title=\"Impact of Immune Cells on IgA Vasculitis via Metabolites and Inflammatory Cytokines\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/09\/impact-of-immune-cells-on-iga-vasculitis-via-metabolites-and-inflammatory-cytokines\/\" aria-label=\"Read more about Impact of Immune Cells on IgA Vasculitis via Metabolites and Inflammatory Cytokines\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/09\/combined-immunodeficiency-associated-with-two-novel-carmil2-mutations-a-case-series\/\">Combined Immunodeficiency Associated with Two Novel CARMIL2 Mutations: A Case Series<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-09T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">9 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 10;45(1):156. doi: 10.1007\/s10875-025-01956-1. ABSTRACT Combined immunodeficiency due to CARMIL2 mutations is a rare autosomal recessive primary immunodeficiency characterized by impaired T-cell activation and function, leading to diverse clinical manifestations. Fewer than 50 cases have been reported worldwide. We describe the clinical and genetic features of five patients from Palestine with &#8230; <a title=\"Combined Immunodeficiency Associated with Two Novel CARMIL2 Mutations: A Case Series\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/09\/combined-immunodeficiency-associated-with-two-novel-carmil2-mutations-a-case-series\/\" aria-label=\"Read more about Combined Immunodeficiency Associated with Two Novel CARMIL2 Mutations: A Case Series\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/07\/fungal-infections-a-stealthy-enemy-in-patients-with-chronic-granulomatous-disease-a-28-years-experience-from-north-india\/\">Fungal Infections &#8211; a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years&#8217; Experience from North India<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-07T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">7 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 7;45(1):153. doi: 10.1007\/s10875-025-01940-9. ABSTRACT Fungal infections contribute to a significant disease burden in patients with chronic granulomatous disease (CGD). While the presentation may differ depending on genotype and environmental exposure to fungus, associated mortality rates are universally high. This is a retrospective study wherein medical records of patients diagnosed with &#8230; <a title=\"Fungal Infections &#8211; a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years&#8217; Experience from North India\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/07\/fungal-infections-a-stealthy-enemy-in-patients-with-chronic-granulomatous-disease-a-28-years-experience-from-north-india\/\" aria-label=\"Read more about Fungal Infections &#8211; a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years&#8217; Experience from North India\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/07\/dual-targeted-therapy-with-baricitinib-and-anifrolumab-in-infantile-spondyloenchondrodysplasia-with-immune-dysregulation\/\">Dual Targeted Therapy with Baricitinib and Anifrolumab in Infantile Spondyloenchondrodysplasia with Immune Dysregulation<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-07T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">7 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 8;45(1):155. doi: 10.1007\/s10875-025-01954-3. NO ABSTRACT PMID:41203937 | DOI:10.1007\/s10875-025-01954-3<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/07\/next-generation-sequencing-and-other-second-tier-tests-in-newborn-screening-for-x-linked-agammaglobulinemia\/\">Next-generation Sequencing and Other Second Tier Tests in Newborn Screening for (X-linked) Agammaglobulinemia<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-07T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">7 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 8;45(1):154. doi: 10.1007\/s10875-025-01927-6. ABSTRACT PURPOSE: Patients with X-linked agammaglobulinemia (XLA) suffer from severe, recurrent infections potentially leading to life-threatening complications. Early diagnosis and timely treatment can prevent infections and secondary complications, emphasizing a role for newborn screening (NBS). NBS for XLA is based on quantification of kappa-deleting recombination excision circles &#8230; <a title=\"Next-generation Sequencing and Other Second Tier Tests in Newborn Screening for (X-linked) Agammaglobulinemia\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/07\/next-generation-sequencing-and-other-second-tier-tests-in-newborn-screening-for-x-linked-agammaglobulinemia\/\" aria-label=\"Read more about Next-generation Sequencing and Other Second Tier Tests in Newborn Screening for (X-linked) Agammaglobulinemia\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/05\/consecutive-non-aspergillus-fungal-invasive-infections-in-chronic-granulomatous-disease-data-from-the-french-national-reference-center-for-primary-immunodeficiencies-and-literature-review\/\">Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-05T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">5 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 6;45(1):152. doi: 10.1007\/s10875-025-01903-0. ABSTRACT BACKGROUND: Non-Aspergillus invasive fungal infections (NAFI) are increasingly reported in patients with Chronic Granulomatous Disease (CGD), but precise clinical descriptions remain scarce. OBJECTIVE AND METHODS: We conducted a retrospective analysis of NAFI cases among CGD patients in the French National Registry of Primary Immunodeficiencies (CEREDIH) and &#8230; <a title=\"Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/05\/consecutive-non-aspergillus-fungal-invasive-infections-in-chronic-granulomatous-disease-data-from-the-french-national-reference-center-for-primary-immunodeficiencies-and-literature-review\/\" aria-label=\"Read more about Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/04\/overrepresentation-of-germline-immune-related-gene-variants-in-patients-with-acquired-bone-marrow-failure\/\">Overrepresentation of Germline Immune-Related Gene Variants in Patients with Acquired Bone Marrow Failure<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-04T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">4 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 5;45(1):150. doi: 10.1007\/s10875-025-01951-6. ABSTRACT PURPOSE: Bone marrow failure (BMF) in idiopathic aplastic anemia (AA) and hypoplastic myelodysplastic neoplasms (MDS-h) results from the destruction of hematopoietic progenitors by autoreactive T cells; however, the molecular events driving the pathogenesis of these disorders remain unclear. We therefore applied whole-exome sequencing (WES) in AA &#8230; <a title=\"Overrepresentation of Germline Immune-Related Gene Variants in Patients with Acquired Bone Marrow Failure\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/04\/overrepresentation-of-germline-immune-related-gene-variants-in-patients-with-acquired-bone-marrow-failure\/\" aria-label=\"Read more about Overrepresentation of Germline Immune-Related Gene Variants in Patients with Acquired Bone Marrow Failure\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/04\/jak-inhibition-in-stat1-gain-of-function-associated-histoplasmosis-and-hlh\/\">JAK Inhibition in STAT1 Gain-of-Function-Associated Histoplasmosis and HLH<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-11-04T12:00:00+01:00\" class=\"wp-block-latest-posts__post-date\">4 de November de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Nov 5;45(1):151. doi: 10.1007\/s10875-025-01900-3. NO ABSTRACT PMID:41188583 | DOI:10.1007\/s10875-025-01900-3<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/21\/beyond-the-classical-triad-atypical-presentations-and-regulatory-t-cell-phenotyping-in-a-cohort-of-ipex-patients\/\">Beyond the Classical Triad: Atypical Presentations and Regulatory T Cell Phenotyping in a Cohort of IPEX Patients<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-21T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">21 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 21;45(1):148. doi: 10.1007\/s10875-025-01934-7. ABSTRACT BACKGROUND: Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked(IPEX) syndrome caused by FOXP3 mutations is rare. FOXP3 is a transcription factor required for the regulatory T cell (Treg) development\/function. AIM: We aimed to characterize the clinical, immunologic, and genetic features of a single-center cohort of IPEX syndrome. PATIENTS &#8230; <a title=\"Beyond the Classical Triad: Atypical Presentations and Regulatory T Cell Phenotyping in a Cohort of IPEX Patients\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/21\/beyond-the-classical-triad-atypical-presentations-and-regulatory-t-cell-phenotyping-in-a-cohort-of-ipex-patients\/\" aria-label=\"Read more about Beyond the Classical Triad: Atypical Presentations and Regulatory T Cell Phenotyping in a Cohort of IPEX Patients\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/21\/type-i-ifns-decrease-sars-cov-2-replication-in-human-cardiomyocytes-and-increase-cytokine-production-in-macrophages\/\">Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-21T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">21 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 21;45(1):149. doi: 10.1007\/s10875-025-01943-6. ABSTRACT The cellular basis of COVID-19 severity in patients with deficiencies in type I IFN immunity remains unclear. In this study, we differentiated cardiomyocytes and macrophages from IFNAR1 competent (IFNAR1comp) and deficient (IFNAR1def) induced pluripotent stem cells (iPSCs), and analyzed virus replication and cytokine production after exposure &#8230; <a title=\"Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/21\/type-i-ifns-decrease-sars-cov-2-replication-in-human-cardiomyocytes-and-increase-cytokine-production-in-macrophages\/\" aria-label=\"Read more about Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/20\/novel-syk-variant-causes-enhanced-syk-autophosphorylation-and-pi3k-activation-in-an-antibody-deficient-patient\/\">Novel SYK Variant Causes Enhanced SYK Autophosphorylation and PI3K Activation in an Antibody-Deficient Patient<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-20T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">20 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 20;45(1):147. doi: 10.1007\/s10875-025-01950-7. ABSTRACT BACKGROUND: Inborn errors of immunity (IEI) affecting B-cell receptor signaling cause predominantly antibody deficiency (PAD) with varying degrees of severity. Recently, four heterozygous variants in SYK were reported to cause hypogammaglobulinemia, multiorgan inflammatory disease and diffuse large B-cell lymphoma. OBJECTIVE: We aimed to unravel the genetic &#8230; <a title=\"Novel SYK Variant Causes Enhanced SYK Autophosphorylation and PI3K Activation in an Antibody-Deficient Patient\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/20\/novel-syk-variant-causes-enhanced-syk-autophosphorylation-and-pi3k-activation-in-an-antibody-deficient-patient\/\" aria-label=\"Read more about Novel SYK Variant Causes Enhanced SYK Autophosphorylation and PI3K Activation in an Antibody-Deficient Patient\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/20\/a-novel-hypomorphic-stat3-gene-variant-in-a-7-year-old-male-with-hyper-ige-syndrome\/\">A Novel Hypomorphic STAT3 Gene Variant in a 7-year-old Male with Hyper-IgE Syndrome<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-20T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">20 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 20;45(1):146. doi: 10.1007\/s10875-025-01942-7. NO ABSTRACT PMID:41114900 | DOI:10.1007\/s10875-025-01942-7<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/17\/disseminated-histoplasmosis-in-very-early-diagnosed-de-novo-stat3-hies\/\">Disseminated Histoplasmosis in Very Early Diagnosed De Novo STAT3-HIES<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-17T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">17 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 17;45(1):145. doi: 10.1007\/s10875-025-01923-w. NO ABSTRACT PMID:41105277 | DOI:10.1007\/s10875-025-01923-w<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/16\/stool-screening-for-campylobacter-species-in-hypogammaglobulinemic-patients-receiving-immunoglobulin-therapy\/\">Stool Screening for Campylobacter Species in Hypogammaglobulinemic Patients Receiving Immunoglobulin Therapy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-16T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">16 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 16;45(1):143. doi: 10.1007\/s10875-025-01949-0. ABSTRACT Hypogammaglobulinemia (HG) predisposes patients to gastrointestinal Campylobacter infections. This prospective study determined the prevalence of Campylobacter in stool samples from patients with immunoglobulin (Ig)-substituted HG at Bordeaux University Hospital. 73 patients (42 women, median age: 61) receiving Ig substitution therapy were enrolled from July 2022 to &#8230; <a title=\"Stool Screening for Campylobacter Species in Hypogammaglobulinemic Patients Receiving Immunoglobulin Therapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/16\/stool-screening-for-campylobacter-species-in-hypogammaglobulinemic-patients-receiving-immunoglobulin-therapy\/\" aria-label=\"Read more about Stool Screening for Campylobacter Species in Hypogammaglobulinemic Patients Receiving Immunoglobulin Therapy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/16\/epstein-barr-virus-associated-smooth-muscle-tumors-in-inborn-errors-of-immunity-a-single-center-case-series-and-literature-overview\/\">Epstein-Barr Virus-Associated Smooth Muscle Tumors in inborn Errors of Immunity: A single-center Case Series and Literature Overview<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-16T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">16 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 16;45(1):144. doi: 10.1007\/s10875-025-01936-5. ABSTRACT BACKGROUND: Primary immunodeficiency disease (PID)\/Inborn Errors of Immunity (IEI) with T-cell dysfunction is well-known for susceptibility to opportunistic\/viral infections. Epstein-Barr virus-positive smooth muscle tumor (EBV-SMT) is a rare entity primarily seen in the setting of immunodeficiency, such as transplantation, HIV\/AIDS, and IEI. AIM: This study aimed &#8230; <a title=\"Epstein-Barr Virus-Associated Smooth Muscle Tumors in inborn Errors of Immunity: A single-center Case Series and Literature Overview\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/16\/epstein-barr-virus-associated-smooth-muscle-tumors-in-inborn-errors-of-immunity-a-single-center-case-series-and-literature-overview\/\" aria-label=\"Read more about Epstein-Barr Virus-Associated Smooth Muscle Tumors in inborn Errors of Immunity: A single-center Case Series and Literature Overview\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/09\/correction-to-self-reported-clinical-outcomes-and-quality-of-life-in-agammaglobulinemia-the-importance-of-an-early-diagnosis\/\">Correction to: Self-reported Clinical Outcomes and Quality of Life in Agammaglobulinemia: the Importance of an Early Diagnosis<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-09T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">9 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 9;45(1):142. doi: 10.1007\/s10875-025-01944-5. NO ABSTRACT PMID:41065887 | DOI:10.1007\/s10875-025-01944-5<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/01\/the-targets-of-immune-adverse-events-in-cancer-immunotherapy-by-combined-check-point-inhibitors-resemble-those-seen-in-ipex-patients\/\">The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-10-01T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">1 de October de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Oct 1;45(1):141. doi: 10.1007\/s10875-025-01929-4. ABSTRACT INTRODUCTION: Specific determinants of target-organ damage in autoimmune diseases are complex and multifactorial, several genetic and environmental factors are recognized but mostly remain unknown. Immunotherapy with &#8220;check-point inhibitors&#8221; (CPI) is complicated by immune related adverse events (IRAE), occurring in a large fraction of patients, with organ-specific &#8230; <a title=\"The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/10\/01\/the-targets-of-immune-adverse-events-in-cancer-immunotherapy-by-combined-check-point-inhibitors-resemble-those-seen-in-ipex-patients\/\" aria-label=\"Read more about The Targets of Immune Adverse Events in Cancer Immunotherapy by Combined Check-point Inhibitors Resemble those Seen in IPEX Patients\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/a-child-with-chronic-mucocutaneous-candidiasis-harbors-a-novel-gain-of-function-mutation-in-stat1\/\">A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-09-30T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">30 de September de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Sep 30;45(1):137. doi: 10.1007\/s10875-025-01937-4. ABSTRACT OBJECTIVE: Germline heterozygous gain-of-function (GOF) mutations in STAT1 impair IL-17-mediated immunity, resulting in carriers&#8217; susceptibility to chronic mucocutaneous candidiasis (CMC). JAK inhibitors have shown therapeutic effectiveness in patients with STAT1-GOF mutations. METHODS: The mutation was detected using whole-exome sequencing (WES) and confirmed by Sanger sequencing. The &#8230; <a title=\"A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/a-child-with-chronic-mucocutaneous-candidiasis-harbors-a-novel-gain-of-function-mutation-in-stat1\/\" aria-label=\"Read more about A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/to-the-editor-cebpe-related-immunodeficiency-mimicking-acute-myeloid-leukemia-a-diagnostic-pitfall-in-pediatric-autoinflammatory-disease\/\">To the Editor, &#8220;CEBPE-Related Immunodeficiency Mimicking Acute Myeloid Leukemia: A Diagnostic Pitfall in Pediatric Autoinflammatory Disease&#8221;<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-09-30T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">30 de September de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Sep 30;45(1):132. doi: 10.1007\/s10875-025-01928-5. NO ABSTRACT PMID:41026272 | DOI:10.1007\/s10875-025-01928-5<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/five-cgd-linked-cybb-mutations-in-chinese-patients-insights-into-predicting-ifn-%ce%b3-treatment-efficacy\/\">Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-\u03b3 Treatment Efficacy<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-09-30T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">30 de September de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Sep 30;45(1):131. doi: 10.1007\/s10875-025-01926-7. ABSTRACT BACKGROUND: The CYBB gene encodes the gp91-phox protein, a critical component of the NADPH oxidase complex involved in pathogen clearance. Mutations in CYBB are associated with chronic granulomatous disease (CGD), leading to recurrent bacterial infections. OBJECTIVE: To understand the genetic causes of Chinese CGD patients. METHODS: &#8230; <a title=\"Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-\u03b3 Treatment Efficacy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/five-cgd-linked-cybb-mutations-in-chinese-patients-insights-into-predicting-ifn-%ce%b3-treatment-efficacy\/\" aria-label=\"Read more about Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-\u03b3 Treatment Efficacy\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/diagnostic-and-monitoring-strategies-for-vexas-syndrome-evaluating-sanger-sequencing-ngs-and-the-swim-score\/\">Diagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-09-30T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">30 de September de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Sep 30;45(1):138. doi: 10.1007\/s10875-025-01932-9. ABSTRACT VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic UBA1 variants, but there are no standardized criteria for genetic testing or diagnostics. This study compared Sanger sequencing and next-generation sequencing (NGS) for detecting UBA1 variants in patients with suspected VEXAS, assessed the ability of Sanger &#8230; <a title=\"Diagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/diagnostic-and-monitoring-strategies-for-vexas-syndrome-evaluating-sanger-sequencing-ngs-and-the-swim-score\/\" aria-label=\"Read more about Diagnostic and Monitoring Strategies for VEXAS Syndrome: Evaluating Sanger Sequencing, NGS, and the SWIM-Score\">Read more<\/a><\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/cvid-enteropathy-is-difficult-to-treat-and-shows-a-heterogeneous-histopathology\/\">CVID Enteropathy Is Difficult To Treat and Shows a Heterogeneous Histopathology<\/a><div class=\"wp-block-latest-posts__post-author\">by inmunoadmin<\/div><time datetime=\"2025-09-30T12:00:00+02:00\" class=\"wp-block-latest-posts__post-date\">30 de September de 2025<\/time><div class=\"wp-block-latest-posts__post-excerpt\">J Clin Immunol. 2025 Sep 30;45(1):129. doi: 10.1007\/s10875-025-01920-z. ABSTRACT PURPOSE: Enteropathy is a non-infectious complication in Common Variable Immune Deficiency (CVID) associated with increased morbidity and mortality. We characterized this group of CVID enteropathy (CVID-E) patients and investigated the effectiveness of immunosuppressive treatments on its clinical course. METHOD: We identified patients with CVID-E in two &#8230; <a title=\"CVID Enteropathy Is Difficult To Treat and Shows a Heterogeneous Histopathology\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/09\/30\/cvid-enteropathy-is-difficult-to-treat-and-shows-a-heterogeneous-histopathology\/\" aria-label=\"Read more about CVID Enteropathy Is Difficult To Treat and Shows a Heterogeneous Histopathology\">Read more<\/a><\/div><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":772,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1531","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/1531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=1531"}],"version-history":[{"count":1,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/1531\/revisions"}],"predecessor-version":[{"id":1532,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/pages\/1531\/revisions\/1532"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media\/772"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=1531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}